NASDAQ:INM InMed Pharmaceuticals (INM) Stock Price, News & Analysis $1.74 +0.01 (+0.29%) As of 01:45 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About InMed Pharmaceuticals Stock (NASDAQ:INM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get InMed Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.58▼$1.9950-Day Range$0.62▼$1.7352-Week Range$0.58▼$7.98Volume525,661 shsAverage Volume1.10 million shsMarket Capitalization$5.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview InMed Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia, that is dedicated to the discovery and development of novel therapeutics derived from cannabinoids. Leveraging a proprietary drug discovery engine, the company works to identify, design and optimize cannabinoid-based molecules with the goal of addressing diseases that have significant unmet medical needs. InMed’s integrated business model combines research, development and manufacturing capabilities under one roof to streamline the progression of promising assets from preclinical studies into human trials. The company’s pipeline features multiple lead programs targeting both neurological and dermatological disorders. Among these, INM-755 is being developed for rare blistering skin disorders and other dermal conditions, while INM-088 is focused on neuroprotective applications such as glaucoma and glioblastoma. InMed’s approach emphasizes the selection of specific cannabinoid compounds based on their pharmacological profiles and the engineering of drug delivery systems that enhance stability, bioavailability and patient compliance. To support its research and clinical objectives, InMed owns BayMedica, a wholly owned subsidiary specializing in the production of high-purity cannabinoid materials under current Good Manufacturing Practices (cGMP). Operating out of a facility in California, BayMedica supplies both internal pipeline programs and external pharmaceutical partners with consistent, analytically characterized cannabinoids. This vertically integrated capability helps mitigate supply chain risks and ensures that InMed can maintain control over critical stages of its development process. Since its founding, InMed has assembled a management team with deep expertise in biotechnology, pharmaceuticals and cannabinoid science. Led by President and Chief Executive Officer Robert C. Loop Jr., the company continues to expand its intellectual property portfolio while advancing multiple candidates toward clinical milestones. InMed serves patients and research collaborators across North America and is actively exploring strategic partnerships to accelerate the delivery of its cannabinoid-based therapies to global markets.AI Generated. May Contain Errors. Read More InMed Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreINM MarketRank™: InMed Pharmaceuticals scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingInMed Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageInMed Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about InMed Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of InMed Pharmaceuticals is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InMed Pharmaceuticals is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInMed Pharmaceuticals has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.08% of the float of InMed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverInMed Pharmaceuticals has a short interest ratio ("days to cover") of 1.16, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InMed Pharmaceuticals has recently decreased by 62.91%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInMed Pharmaceuticals does not currently pay a dividend.Dividend GrowthInMed Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.32 News SentimentInMed Pharmaceuticals has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for InMed Pharmaceuticals this week, compared to 1 article on an average week.Search Interest6 people have searched for INM on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added InMed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.1 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $721,569.00 in company stock, which represents 12.5646% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, InMed Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $721,569.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders0.85% of the stock of InMed Pharmaceuticals is held by insiders.Percentage Held by Institutions20.12% of the stock of InMed Pharmaceuticals is held by institutions.Read more about InMed Pharmaceuticals' insider trading history. Receive INM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INM Stock News HeadlinesInMed Pharmaceuticals (NASDAQ:INM) Major Shareholder Acquires $721,568.54 in StockMay 22 at 7:45 AM | insidertrades.comINM stock alert: What to know as InMed, Mentari announce mergerMay 21 at 3:13 PM | msn.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.May 22 at 1:00 AM | Behind the Markets (Ad)$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of InMed Pharmaceuticals, Inc. (NASDAQ: INM)May 20 at 11:02 AM | globenewswire.comINM Share News TodayMay 19 at 12:18 AM | uk.investing.comA migraine drugmaker heads to the public markets through reverse mergerMay 19 at 12:18 AM | finance.yahoo.comInMed-Mentari migraine merger backed by $290 million financing reshapes company strategy (INM)May 19 at 12:18 AM | msn.comInMed and Mentari announce all-stock merger dealMay 19 at 12:18 AM | msn.comSee More Headlines INM Stock Analysis - Frequently Asked Questions How have INM shares performed this year? InMed Pharmaceuticals' stock was trading at $1.06 on January 1st, 2026. Since then, INM stock has increased by 63.7% and is now trading at $1.7350. How were InMed Pharmaceuticals' earnings last quarter? InMed Pharmaceuticals Inc. (NASDAQ:INM) posted its earnings results on Wednesday, May, 6th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($94.44) by $93.75. InMed Pharmaceuticals had a negative net margin of 132.87% and a negative trailing twelve-month return on equity of 80.85%. When did InMed Pharmaceuticals' stock split? InMed Pharmaceuticals shares reverse split on Wednesday, September 7th 2022.The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of InMed Pharmaceuticals? Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of InMed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that InMed Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Tesla (TSLA) and PayPal (PYPL). Company Calendar Last Earnings5/06/2026Today5/22/2026Fiscal Year End6/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 3 days ago, INM's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INM CIK1728328 Webwww.inmedpharma.com Phone604-669-7207FaxN/AEmployees10Year Founded2014Profitability EPS (Trailing Twelve Months)($2.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.16 million Net Margins-132.87% Pretax Margin-186.17% Return on Equity-80.85% Return on Assets-68.11% Debt Debt-to-Equity RatioN/A Current Ratio3.12 Quick Ratio3.12 Sales & Book Value Annual Sales$4.94 million Price / Sales1.16 Cash FlowN/A Price / Cash FlowN/A Book Value$2.08 per share Price / Book0.83Miscellaneous Outstanding Shares3,310,000Free Float3,286,000Market Cap$5.74 million OptionableNot Optionable Beta0.57 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:INM) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...InvestorPlace | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredHidden on Tesla's filing: A $12 billion "super startup"Tesla's most recent SEC filing contains a single line showing $12 billion in revenue from a new venture Elon M...Banyan Hill Publishing | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
